<DOC>
	<DOCNO>NCT00228176</DOCNO>
	<brief_summary>Objectives : - Primary : To evaluate effect rimonabant 20-mg daily comparison placebo , quantitative progression atherosclerosis assess carotid artery intima-media thickness ( CIMT ) - Secondary : To evaluate safety tolerability rimonabant regimen study population atherosclerosis patient .</brief_summary>
	<brief_title>Atherosclerosis Underlying Development Assessed Intima-Media Thickness Patients Rimonabant</brief_title>
	<detailed_description>This Phase III , prospective , multicentre , multinational , randomize , double-blind , placebo-controlled , 2-arm parallel group trial ( rimonabant 20-mg od v placebo ) . There three-stage screening process include successively Screening visit , Screening CIMT validation Screening CIMT Imaging Core Laboratory . Patients comply inclusion exclusion criterion randomize one 2 treatment group less two week Screening visit . Study drug ( rimonabant 20 mg od match placebo ) administer 30 32 month . At inclusion , patient counsel follow mild hypocaloric diet , increase exercise level , stop smoking ( smoker ) . Glucose/lipid parameter assess Baseline every 6 month Month 30 visit . CIMT perform Baseline every 6 month final assessment Month 30 ( primary endpoint ) .A post-treatment follow-up visit Month 35 allow collection adverse event cardiovascular outcome occur last study drug administration</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Written sign inform consent Age great equal 55 year Abdominal obesity define waist circumference &gt; 88 cm ( 35 inch ) woman &gt; 102 cm ( 40 inch ) men Metabolic syndrome diagnose basis least two follow additional risk factor : 1 . Triglyceride level equal great 150 mg/dL 2 . HDL cholesterol le 40 mg/dL men 50 mg/dL woman 3 . Fasting glucose equal great 110 mg/dL 4 . High blood pressure define equal great 140 mmHg systolic and/or equal great 90 mmHg diastolic screen visit current treatment antihypertensive medication . Ultrasonographic evidence Screening quantitative Bmode ultrasound image minimal CIMT measurement great equal 0.7 mm either far wall common carotid artery , maximal CIMT measurement le 3 mm carotid artery segment . All 6 carotid artery segment must ultrasound image CIMT measurement Screening CIMT record deem acceptable CIMT image quality , demonstrate adherence CIMT interrogation protocol , determine Imaging Core Laboratory 's assessment . History low calorie diet surgical procedure weight loss within 6 month prior screen visit Obesity know endocrine origin Uncontrolled diabetes , i.e . HbA1c &gt; 10 % Anticipated survival le 27 month Presence severe medical psychological condition , opinion Investigator , would compromise subject 's safety successful participation study Presence condition ( e.g . geographic , social , ) , actual anticipate , Investigator feel would restrict limit subject 's participation duration study Receipt investigational treatment ( drug device ) within 30 day prior Screening Previous participation rimonabant study Total occlusion carotid artery segment Previous history carotid intervention Patient consider high risk carotid intervention next 27 month</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Carotid Atherosclerosis</keyword>
</DOC>